Last $166.10 USD
Change Today 0.00 / 0.00%
Volume 0.0
IDXX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

idexx laboratories inc (IDXX) Snapshot

Open
$167.63
Previous Close
$167.06
Day High
$168.28
Day Low
$164.62
52 Week High
01/23/15 - $168.51
52 Week Low
02/3/14 - $108.58
Market Cap
7.9B
Average Volume 10 Days
455.3K
EPS TTM
$3.89
Shares Outstanding
47.7M
EX-Date
--
P/E TM
42.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for IDEXX LABORATORIES INC (IDXX)

idexx laboratories inc (IDXX) Related Bloomberg News

View More Bloomberg News

idexx laboratories inc (IDXX) Related Businessweek News

No Related Businessweek News Found

idexx laboratories inc (IDXX) Details

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company operates through Companion Animal Group, Water, Livestock and Poultry Diagnostics, Dairy, and OPTI Medical segments. The company primary offers point-of-care veterinary diagnostic products comprising instruments and consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; and practice management systems and services, and digital radiography systems used by veterinarians. It also provides biological materials testing and laboratory diagnostic instruments and services used by the biomedical research community; diagnostic and health-monitoring products for livestock and poultry; products that test water for certain microbiological contaminants; products that test milk for antibiotic residues and other contaminants; and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market. The company markets and sells its products through marketing, sales, and technical service groups, as well as independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

5,700 Employees
Last Reported Date: 02/18/14
Founded in 1983

idexx laboratories inc (IDXX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $784.6K
Executive Vice President
Total Annual Compensation: $396.2K
Executive Vice President
Total Annual Compensation: $396.2K
Executive Vice President
Total Annual Compensation: $396.2K
Vice President of Finance
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

idexx laboratories inc (IDXX) Key Developments

IDEXX Laboratories Launches Its New Kidney Test Called SDMA

IDEXX Laboratories announced that it launched its new kidney test, called SDMA to transform the way veterinarians diagnose and treat kidney disease in cats and dogs. The company added that the new IDEXX SDMA test has been shown to detect kidney disease when only 40% function has been lost, on average, and in some cases even earlier, allowing veterinarians to provide more effective intervention, including prescription of therapeutic diets, renal protective drugs and avoidance of renal toxic drugs. This new test incorporates proprietary technology that allows SDMA to be measured on routine high throughput clinical chemistry analyzers used in its reference labs in a highly cost effective fashion and at the same rapid turnaround time as the rest of a chemistry panel, according to the company. In conjunction, the company intends to include the SDMA kidney test in all routine reference lab chemistry profiles at no additional cost to the customer. More than half request for a chemistry panel and almost all customers who use IDEXX as their primary reference lab routinely request lab requisitions that include chemistry testing.

IDEXX Laboratories, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 07:30 AM

IDEXX Laboratories, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jonathan W. Ayers, Chairman, Chief Executive Officer and President.

IDEXX Laboratories, Inc. Agrees to Issue and Sell $75,000,000 of its 3.25% Series A Senior Notes and $75,000,000 of its 3.72% Series B Senior Notes

On December 19, 2014, IDEXX Laboratories, Inc. entered into a Multicurrency Note Purchase and Private Shelf Agreement among the company, Metropolitan Life Insurance Company, and each of the accredited institutional purchasers named therein pursuant to which the company agreed to issue and sell $75,000,000 of its 3.25% Series A Senior Notes having a seven-year term (the 2022 Notes) at a purchase price of 100% of the principal amount of the 2022 Notes, and $75,000,000 of its 3.72% Series B Senior Notes having a twelve-year term (the 2027 Notes) at a purchase price of 100% of the principal amount of the 2027 Notes. The issuance, sale and purchase of the 2022 Notes and 2027 Notes are subject to the satisfaction of standard closing conditions for private placement term note transactions, and the company expects that the issuance, sale and purchase of the 2022 Notes and 2027 Notes will close in February 2015. The company intends to use the net proceeds from the issuance and sale of the 2022 Notes and 2027 Notes pursuant to the agreement for general corporate purposes, including repaying amounts outstanding under its revolving credit facility. The agreement also provides for an uncommitted shelf facility by which the company may request that MetLife purchase, over the next three years, up to $50,000,000 of additional senior promissory notes of the company at a fixed interest rate and with a maturity date not to exceed fifteen years. MetLife is under no obligation to purchase any of the Shelf Notes. The interest rate of any series of Shelf Notes will be determined at the time of purchase. The proceeds of any series of Shelf Notes will be used as specified in the request for purchase with respect to such series, subject to compliance with the requirement in the Agreement that the proceeds of the Notes will be used only for general corporate purposes. If and when issued, the 2022 Notes will bear interest at a fixed rate of 3.25% and mature seven years after the original issuance date, and the 2027 Notes will bear interest at a fixed rate of 3.72% and mature twelve years after the original issuance date. In addition, the Company may prepay the Notes, if and when issued, in an amount not less than $1,000,000 in the case of Dollar denominated Notes, 1,000,000 in the case of Sterling denominated Notes and 1,000,000 in the case of Euro denominated Notes (and otherwise in multiples of $100,000, 100,000 or 100,000, respectively) of such series of Notes then outstanding at 100% of the principal amount so prepaid, plus the applicable make-whole amount (as set in the Agreement) upon no more than 60 or less than 10 days' written notice to the holders of the applicable Notes. In addition, if and when the Notes are issued, in the event of a change in control (as defined in the Agreement) of the Company or upon the disposition of certain assets of the Company the proceeds of which are not reinvested (as set in the Agreement), at the option of the holders of the Notes, the Company may be required to prepay all or a portion of the Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest. If and when the Notes are issued, the obligations of the Company under the Notes may be accelerated upon the occurrence of an event of default under the Agreement, which includes customary events of default including, without limitation, payment defaults, defaults in the performance of affirmative and negative covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency related defaults, defaults relating to judgments, an ERISA event and the failure to pay specified indebtedness. The Agreement contains affirmative, negative and financial covenants customary for agreements of this type. The negative covenants include restrictions on liens, indebtedness of subsidiaries of the Company, priority indebtedness, fundamental changes, investments, transactions with affiliates, certain restrictive agreements and violations of laws and regulations. The financial covenant is a consolidated leverage ratio test. If and when the Notes are issued, the obligations of the Company will be unconditionally guaranteed by each of its subsidiaries that guarantees the obligations of the Company under a material credit facility (but excluding any foreign subsidiary that does not guarantee indebtedness of the company or any US subsidiaries under a material credit facility).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDXX:US $166.10 USD 0.00

IDXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $50.75 USD -0.14
Hologic Inc $29.62 USD +0.275
Mettler-Toledo International Inc $303.50 USD +0.45
ResMed Inc $67.17 USD +1.93
Cooper Cos Inc/The $162.21 USD +0.46
View Industry Companies
 

Industry Analysis

IDXX

Industry Average

Valuation IDXX Industry Range
Price/Earnings 43.5x
Price/Sales 5.6x
Price/Book 35.2x
Price/Cash Flow 40.0x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDEXX LABORATORIES INC, please visit www.idexx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.